Asset Details
Do you wish to reserve the book?
Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers
Do you wish to request the book?
Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers
2011
Overview
Aim： To investigate the safety, tolerability and pharmacokinetics of intravenous hemoporfin, a novel photosensitive drug for the treatment of port-wine stain （PWS）, in healthy Chinese volunteers following single-dose administration. Methods： Thirty-six healthy Chinese subjects were enrolled. The subjects were administered hemoporfin （2.5, 5, 7.5 or 10 mg/kg） via single-dose intravenous infusion. Pharmacokinetics of the drug were studied in the groups with doses of 2.5, 5 and 7.5 mg/kg, and tolerability was studied in all the 4 groups. Safety and tolerance were evaluated by monitoring adverse events and laboratory parameters, and pharmacokinetics were assessed by determining hemoporfin content with a validated high-performance liquid chromatography with fluorescence detection （HPLC/FLD） method. Results： Mild and transient adverse events occurred in the trial （n=10）, but none were serious, and no subjects were withdrawn from the trial. The gastrointestinal tract adverse events, such as nausea, stomach upset, abdominal pain and vomiting, were observed in the groups with doses of 7.5 and 10 mg/kg. Increased alanine aminotransferase （ALT） concentration was found in 3 subjects, and increased alkaline phosphatase （ALP） concentration in one subject. The ha~f-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively. Cmax and AUC increased with dose for intravenous single-dose administration of hemoporfin in the 2.5, 5, and 7.5 mg/kg groups. Urinary excretion of hemoporfin within 12 h was less than 0.2%. Conclusion： Hemoporfin is safe and well-tolerated in healthy Chinese volunteers at a single intravenous dose of up to 10 mg/kg. It was rapidly cleared from the blood and had a short half-life, which insures a short light-avoidance period.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
